Trials / Not Yet Recruiting
Not Yet RecruitingNCT07493512
Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
A Phase 1b, Open-label Study of Xaluritamig (AMG 509) in Adults With Metastatic Castration-resistant Prostate Cancer
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Amgen · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this trial is to determine the safety profile of xaluritamig at the proposed regimen in adult participants with metastatic castration-resistant prostate cancer (mCRPC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Xaluritamig | Participants will receive xaluritamig via short-term intravenous (IV) infusion. |
Timeline
- Start date
- 2026-05-26
- Primary completion
- 2027-05-27
- Completion
- 2029-11-24
- First posted
- 2026-03-25
- Last updated
- 2026-03-25
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07493512. Inclusion in this directory is not an endorsement.